KLRSHealthcareMicro-Cap
Kalaris Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Kalaris Therapeutics, Inc. (KLRS), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud Research Team · SEC Form 4 & insider trading data analysts
Last updated:
Quick Answer
Are KLRS insiders buying or selling?
Kalaris Therapeutics, Inc. insiders reported 9 open-market buys ($66.8M) and 184 sells ($46.3M) across 193 Form 4 filings — a net buying position of $20.4M.
Source: SEC EDGAR Form 4
Key Statistics (as of May 22, 2026)
Total Form 4 filings
193
SEC EDGAR
Insider filers
16
Insider buys (9)
$66.8M
Insider sells (184)
$46.3M
Insider sentiment
Net buyingNet insider flow of $20.4M in net buying. 1 insider buy in the last 90 days.
Recent KLRS insider transactions
| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 22, 2026 | Srinivas Akkaraju | Director, 10% Owner | Purchase | 244.3K | $4.83 | $1.2M |
| Mar 23, 2026 | Brett R Hagen | Chief Accounting Officer | Sale | 1.9K | $6.72 | $12.9K |
| Feb 18, 2026 | Srinivas Akkaraju | Director, 10% Owner | Purchase | 479.8K | $10.42 | $5.0M |
| Mar 27, 2025 | Brett R Hagen | Chief Accounting Officer | Sale | 907 | $8.97 | $8.1K |
| Feb 24, 2025 | Vikas Sinha | Officer Title: President, Chief Financial Officer and Chief Executive Officer | Sale | 303 | $10.08 | $3.1K |
| Feb 24, 2025 | Brett R Hagen | Chief Accounting Officer | Sale | 96 | $10.08 | $967.28 |
| Feb 24, 2025 | Edward Miller | General Counsel | Sale | 106 | $10.08 | $1.1K |
| Jan 27, 2025 | Edward Miller | General Counsel | Sale | 52 | $9.50 | $494.03 |
| Jan 27, 2025 | Brett R Hagen | Chief Accounting Officer | Sale | 36 | $9.51 | $342.28 |
| Jan 27, 2025 | Vikas Sinha | Officer Title: President, Chief Financial Officer and Chief Executive Officer | Sale | 129 | $9.50 | $1.2K |
| Jan 13, 2025 | Edward Miller | General Counsel | Sale | 409 | $0.44 | $180 |
| Jan 13, 2025 | Brett R Hagen | Chief Accounting Officer | Sale | 332 | $0.44 | $146.11 |
| Jan 13, 2025 | Vikas Sinha | Officer Title: President, Chief Financial Officer and Chief Executive Officer | Sale | 979 | $0.44 | $430.86 |
| Nov 20, 2024 | Brett R Hagen | Chief Accounting Officer | Sale | 554 | $0.55 | $303.87 |
| Nov 20, 2024 | Vikas Sinha | Officer Title: President and Chief Financial Officer | Sale | 3.2K | $0.55 | $1.7K |
| Nov 20, 2024 | Edward Miller | General Counsel | Sale | 432 | $0.55 | $236.95 |
| Nov 20, 2024 | Diana Brainard | Chief Executive Officer | Sale | 8.7K | $0.55 | $4.8K |
| Nov 6, 2024 | Diana Brainard | Chief Executive Officer | Sale | 10.6K | $0.86 | $9.2K |
| Nov 6, 2024 | Edward Miller | General Counsel | Sale | 2.3K | $0.86 | $2.0K |
| Nov 6, 2024 | Brett R Hagen | Chief Accounting Officer | Sale | 1.7K | $0.86 | $1.4K |
| Nov 6, 2024 | Vikas Sinha | Officer Title: President and Chief Financial Officer | Sale | 5.1K | $0.86 | $4.4K |
| Oct 23, 2024 | Vikas Sinha | Officer Title: President and Chief Financial Officer | Sale | 3.4K | $0.77 | $2.6K |
| Oct 23, 2024 | Diana Brainard | Chief Executive Officer | Sale | 9.8K | $0.78 | $7.6K |
| Oct 23, 2024 | Brett R Hagen | Chief Accounting Officer | Sale | 965 | $0.77 | $746.29 |
| Oct 23, 2024 | Edward Miller | General Counsel | Sale | 1.4K | $0.77 | $1.1K |
Showing the 25 most recent of 193 Form 4 filings for Kalaris Therapeutics, Inc..
Most active KLRS insiders
- Brett R Hagen38 filings
- Vikas Sinha32 filings
- Diana Brainard28 filings
- Beek Jeroen B Van24 filings
- Edward Miller24 filings
Ask anything about KLRS insider activity
Use Trabud's AI agent to query Kalaris Therapeutics, Inc.'s Form 4 history in plain English — "Show me KLRS CEO purchases this year" or compare it against any other ticker.
Open the AI agentKLRS insider trading FAQ
Are Kalaris Therapeutics, Inc. insiders buying or selling?
Across 193 SEC Form 4 filings, Kalaris Therapeutics, Inc. (KLRS) insiders reported 9 open-market purchases totaling $66.8M and 184 sales totaling $46.3M. That is a net buying position of $20.4M.
How many insiders trade KLRS stock?
16 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Kalaris Therapeutics, Inc.. The most recent filing was accepted on May 22, 2026.
Where does Trabud get KLRS insider trading data?
All KLRS insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.
Looking for another company? Browse all tracked companies.